Agilent Technologies Secures Patent for CGH Assays
Agilent Technologies Inc. announced that it was awarded a significant patent for comparative genomic hybridization methods. CGH methods help researchers study genetics and cancer in both basic and clinical research.
The U.S. patent (No. 8,232,055) has claims for measuring copy number changes in genomic DNA, covering both one-color and two-color assays using oligonucleotide probes and samples with high-sequence complexity, such as human genomic DNA samples.
Agilent’s copy number method, commercially introduced in 2005, uses long oligonucleotide probes, enabling high specificity and sensitivity. For example, samples containing as low as 8 percent abnormal cells may be confidently analyzed with Agilent’s copy number method.
The method was originally developed to improve upon older copy number assays that use long genomic fragments such as bacterial artificial chromosomes. (BACs often contain repetitive regions.) The method also improves upon other oligonucleotide array assays, which depend on sample preparation methods that remove significant portions of the genomic DNA content. Agilent’s higher-resolution platform allows users to detect much smaller genomic aberrations throughout complex genomes.
- 1Schleicher & Schuell has been purchased by Whatman plc
- 2Detecting chemical weapons with a color-changing film
- 3Scientists get first glimpse of a chemical bond being born
- 4Eurofins acquires BioDiagnostics, Inc.
- 5LGC rebrands reference standards
- 6Live broadcast from inside the nerve cell
- 7Fluorescence spectroscopy using a smartphone
- 8Adulterated foods investigated: modern analytical methods verify that foods are genuine
- 9First-ever view of protein structure may lead to better anxiety drugs
- 10Tattoo-like sensor can detect glucose levels without a painful finger prick